Opinion

Video

BOND-003 Trial and Cretostimogene for Treatment of NMIBC

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
      • Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
      • What are your impressions of the BOND-003 data?
      Related Videos
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      NMIBC Treatment Decisions in the Age of BCG Shortages
      NMIBC Treatment Decisions in the Age of BCG Shortages
      Current Standards of Care and Shifting Strategies in NMIBC
      Current Standards of Care and Shifting Strategies in NMIBC
      1 expert is featured in this series.
      Targeted Therapy in mHSPC: Effects of Mutation Absence
      Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
      Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
      An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
      An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
      1 expert is featured in this series.
      Treatment Strategies for Symptomatic Bone Metastases in mHSPC
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      1 expert in this video
      Adoption of New Treatment Modalities to Treat BPH
      Related Content
      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
      May 21st 2025

      FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

      Hannah Clarke
      The committee voted 4-5 in opposition of a favorable benefit-risk profile.
      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
      May 17th 2025

      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

      Amy M. Pearlman, MD Alex Tatem, MD
      Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      May 9th 2025

      Durvalumab plus BCG significantly improves DFS in NMIBC

      Benjamin P. Saylor Hannah Clarke
      The data are to be presented at an upcoming medical conference.
      Physical function and frailty measures offer distinct insights in patients with bladder cancer
      May 7th 2025

      Physical function and frailty measures offer distinct insights in patients with bladder cancer

      Hannah Clarke
      Data showed that physical function and self-reported frailty assessments were poorly correlated.
      © 2025 MJH Life Sciences

      All rights reserved.